Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ZYUS Life SciencesZLSCF EV-to-EBITDA is -1.45 as of Aug. 07, 2026. The stock has 7 warning signs investors should review. Among 739 Drug Manufacturers companies, ZYUS Life Sciences ranks worse than 135317.86% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, ZYUS Life Sciences's enterprise value is $16.62 Mil.
ZYUS Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-11.45 Mil. Therefore, ZYUS Life Sciences's EV-to-EBITDA for today is -1.45.
The historical rank and industry rank for ZYUS Life Sciences's EV-to-EBITDA or its related term are showing as below:
ZLSCF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -10.94 Med: -2.13 Max: -1.45
Current: -1.45
During the past 5 years, the highest EV-to-EBITDA of ZYUS Life Sciences was -1.45. The lowest was -10.94. And the median was -2.13.
ZLSCF's EV-to-EBITDA is ranked worse than 100% of 739
companies
in the Drug Manufacturers industry
Industry Median: 13.37
vs ZLSCF: -1.45
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
ZYUS Life Sciences (OTCPK:ZLSCF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
ZYUS Life Sciences's PE Ratio (TTM) for today is calculated as:
ZYUS Life Sciences's share price for today is $0.0137.
ZYUS Life Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.196.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for ZYUS Life Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZLSCF vs RMTI, BTAI, MRMD: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ZYUS Life Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ZYUS Life Sciences EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ZYUS Life Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where ZYUS Life Sciences's EV-to-EBITDA falls into.
ZYUS Life Sciences's current Enterprise Value is $16.62 Mil.
ZYUS Life Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ZYUS Life Sciences (ZLSCF) has a EV-to-EBITDA of -1.45 as of Aug. 07, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ZYUS Life Sciences. According to the industry distribution chart, ZYUS Life Sciences ranks #999999 out of 739 companies in the Drug Manufacturers industry.
Is ZYUS Life Sciences' EV-to-EBITDA too high?
ZYUS Life Sciences' current EV-to-EBITDA is -1.45. Based on the distribution chart, ZYUS Life Sciences ranks #999999 out of 739 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does ZYUS Life Sciences' EV-to-EBITDA compare to RMTI and BTAI?
According to the Drug Manufacturers industry distribution chart, ZYUS Life Sciences ranks #999999 out of 739 companies for EV-to-EBITDA. This places ZYUS Life Sciences in the lower half of its industry. The industry median EV-to-EBITDA is 13.37. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.37, based on 739 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on ZYUS Life Sciences. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.37 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ZYUS Life Sciences's current EV-to-EBITDA is -1.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZYUS Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, ZYUS Life Sciences (ZLSCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.60, compared to a current price of $0.01 — trading 97.7% below its estimated fair value. The current EV-to-EBITDA is -1.45. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For ZYUS Life Sciences (ZLSCF), the current EV-to-EBITDA is -1.45 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ZYUS Life Sciences Corp is primarily engaged in the world-wide development and commercialization of cannabinoid-based therapeutics and product candidates. It is a licensed producer and distributor of medical cannabis for both medical and adult recreational access in Canada. The company has one reportable segment: Bio-pharmaceutical Products (including medical cannabis derivatives). Geographically, it operates in Canada; United States; Australia; and European Union.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ZLSCF has been successfully added to your 
